...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Less than spectacular Alzheimer's news careens Biogen's share price.

When the results of Study 201 hit the wire at 4:30 Wednesday afternoon BIIB's share price got wacked by close to 11.5% or about 8 billion market cap in after hours trading. This leaves the door wide open for the cognitive function arm of the BETonMACE trial to dazzle the market if they can show any kind of increase in cognitive function when those results are finally available.

Of course we want to see greater than 30% RRR first in the Top Line Results.

tada

Share
New Message
Please login to post a reply